​

Tango Therapeutics (TNGX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TNGX Stock Forecast

Tango Therapeutics (TNGX) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $42.70, with a high of $69.00 and a low of $24.00. This represents a 38.01% increase from the last price of $30.94.

- $14 $28 $42 $56 $70 High: $69 Avg: $42.7 Low: $24 Last Closed Price: $30.94

TNGX Stock Rating

Tango Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (84.62%), 2 Hold (15.38%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 2 11 Strong Sell Sell Hold Buy Strong Buy

TNGX Price Target Upside V Benchmarks

TypeNameUpside
StockTango Therapeutics38.01%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts51117
Avg Price Target$49.60$41.55$32.88
Last Closing Price$30.94$30.94$30.94
Upside/Downside60.31%34.29%6.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26-93--12
May, 261101--12
Apr, 26191--11
Mar, 26191--11
Feb, 26181--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 09, 2026H.C. Wainwright$66.00$30.98113.04%113.32%
Jun 09, 2026Canaccord Genuity$42.00$30.9335.79%35.75%
Jun 08, 2026Leerink Partners$69.00$31.17121.37%123.01%
Jun 08, 2026Joseph CatanzaroMizuho Securities$36.00$31.0815.83%16.35%
Jun 08, 2026Wolfe Research$35.00$29.5918.28%13.12%
May 15, 2026Joseph CatanzaroMizuho Securities$30.00$24.8720.63%-3.04%
May 14, 2026Piper Sandler$24.00$24.87-3.50%-22.43%
May 14, 2026UBS$55.00$24.87121.15%77.76%
May 14, 2026Wedbush$33.00$23.9837.61%6.66%
May 14, 2026Maury RaycroftJefferies$27.00$25.515.84%-12.73%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 09, 2026H.C. WainwrightBuyBuyhold
Jun 08, 2026Wolfe ResearchOutperformupgrade
Jun 08, 2026B. RileyBuyBuyhold
May 14, 2026Piper SandlerOverweightNeutraldowngrade
May 14, 2026WedbushOutperformOutperformhold
May 14, 2026JefferiesBuyHolddowngrade
Apr 27, 2026CitigroupBuyBuyhold
Mar 27, 2026B. RileyBuyBuyhold
Mar 05, 2026JefferiesBuyBuyhold
Jan 16, 2026Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.94$-1.23$-1.08$-1.19$-0.87---
Avg Forecast$-1.04$-1.26$-1.07$-1.20$-1.43$-1.48$-1.62$-1.38
High Forecast$-0.76$-1.07$-1.03$-1.12$-1.24$-1.21$-1.22$-1.11
Low Forecast$-1.70$-1.81$-1.11$-1.27$-1.58$-1.61$-2.06$-2.24
Surprise %-9.62%-2.38%0.93%-0.83%-39.16%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$37.04M$24.86M$36.53M$42.07M$62.38M---
Avg Forecast$37.91M$24.78M$38.63M$46.01M$29.34M$28.57M$89.88M$34.68M
High Forecast$56.69M$33.21M$41.54M$53.84M$43.20M$28.79M$132.73M$51.22M
Low Forecast$30.17M$21.97M$36.78M$43.14M$24.86M$28.35M$76.37M$29.47M
Surprise %-2.30%0.32%-5.44%-8.56%112.63%---

Net Income Forecast

$-250M $-210M $-170M $-130M $-90M $-50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-58.23M$-108.18M$-101.74M$-130.30M$-101.59M---
Avg Forecast$-97.98M$-118.85M$-101.74M$-113.10M$-133.31M$-133.46M$-154.99M$-130.51M
High Forecast$-71.95M$-101.33M$-97.38M$-105.95M$-117.31M$-114.67M$-115.54M$-105.00M
Low Forecast$-161.05M$-171.40M$-104.95M$-120.26M$-149.31M$-152.26M$-194.45M$-211.40M
Surprise %-40.56%-8.98%-15.21%-23.79%---

TNGX Forecast FAQ

Is Tango Therapeutics stock a buy?

Tango Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Tango Therapeutics is a favorable investment for most analysts.

What is Tango Therapeutics's price target?

Tango Therapeutics's price target, set by 13 Wall Street analysts, averages $42.7 over the next 12 months. The price target range spans from $24 at the low end to $69 at the high end, suggesting a potential 38.01% change from the previous closing price of $30.94.

How does Tango Therapeutics stock forecast compare to its benchmarks?

Tango Therapeutics's stock forecast shows a 38.01% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Tango Therapeutics over the past three months?

  • June 2026: 0% Strong Buy, 75.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 8.33% Strong Buy, 83.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 9.09% Strong Buy, 81.82% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is Tango Therapeutics’s EPS forecast?

Tango Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.48, marking a 70.11% increase from the reported $-0.87 in 2025. Estimates for the following years are $-1.62 in 2027, and $-1.38 in 2028.

What is Tango Therapeutics’s revenue forecast?

Tango Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $28.57M, reflecting a -54.20% decrease from the reported $62.38M in 2025. The forecast for 2027 is $89.88M, and $34.68M for 2028.

What is Tango Therapeutics’s net income forecast?

Tango Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-133M, representing an 31.37% increase from the reported $-102M in 2025. Projections indicate $-155M in 2027, and $-131M in 2028.